Biomerica Will Market Cancer Test in Japan

Biomerica Inc., a Newport Beach medical technology company, said Monday it will market its 10-minute prostate cancer test to hospitals and physicians in Japan through Nihon Schering, a unit of Schering AG. Financial terms were not disclosed.

Biomerica said last week that Japanese regulators approved the sale of its EZ-PSA test, which detects elevated levels of prostate-specific antigen, an early warning indicator of prostate cancer.